

Stephane Epelbaum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9124717/publications.pdf>

Version: 2024-02-01

95
papers

7,323
citations

218677

26
h-index

74163

75
g-index

109
all docs

109
docs citations

109
times ranked

9454
citing authors

#	ARTICLE	IF	CITATIONS
1	The Accelerated Approval of Aducanumab Invites a Rethink of the Current Model of Drug Development for Alzheimer's Disease. <i>AJOB Neuroscience</i> , 2023, 14, 332-335.	1.1	5
2	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.0	97
3	Subtle postoperative cognitive disorder in preclinical Alzheimer's disease. <i>Experimental Gerontology</i> , 2022, 161, 111715.	2.8	0
4	Identifying health conditions associated with Alzheimer's disease up to 15 years before diagnosis: an agnostic study of French and British health records. <i>The Lancet Digital Health</i> , 2022, 4, e169-e178.	12.3	28
5	Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease with an implantable ultrasound device. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 40.	6.2	30
6	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.8	22
7	Radiological classification of dementia from anatomical MRI assisted by machine learning-derived maps. <i>Journal of Neuroradiology</i> , 2021, 48, 412-418.	1.1	18
8	Reproducible Evaluation of Diffusion MRI Features for Automatic Classification of Patients with Alzheimer's Disease. <i>Neuroinformatics</i> , 2021, 19, 57-78.	2.8	20
9	Predicting the progression of mild cognitive impairment using machine learning: A systematic, quantitative and critical review. <i>Medical Image Analysis</i> , 2021, 67, 101848.	11.6	50
10	AD Course Map charts Alzheimer's disease progression. <i>Scientific Reports</i> , 2021, 11, 8020.	3.3	33
11	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. <i>Alzheimer's and Dementia</i> , 2021, 17, 1528-1553.	0.8	64
12	Primary Progressive Aphasia Associated With <i>GRN</i> Mutations. <i>Neurology</i> , 2021, 97, e88-e102.	1.1	23
13	Clinical and neuropathological diversity of tauopathy in MAPT duplication carriers. <i>Acta Neuropathologica</i> , 2021, 142, 259-278.	7.7	8
14	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , The, 2021, 20, 484-496.	10.2	396
15	A Proposal to Make Biomedical Research into Alzheimer's Disease More Democratic Following an International Survey with Researchers. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 637-645.	2.2	13
16	Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 697234.	3.4	17
17	A machine learning approach to screen for preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 105, 205-216.	3.1	18
18	Changes in the use of psychotropic drugs during the course of Alzheimer's disease: A large-scale longitudinal study of French medical records. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12210.	3.7	0

#	ARTICLE	IF	CITATIONS
19	Clinical diagnosis of Alzheimer's disease: Recommendations of the International Working Group (IWG). <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	3
20	Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis. <i>Statistical Methods in Medical Research</i> , 2020, 29, 151-164.	1.5	30
21	Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 129.	6.2	18
22	Association of plasma YKL-40 with brain amyloid- β^2 levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 96, 22-32.	3.1	18
23	The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12021.	2.4	15
24	A specific pattern of memory errors in asymptomatic at-risk for AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e037385.	0.8	0
25	In vivo characterization of progressive amnesic syndrome due to suspected neurodegenerative non-Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e039587.	0.8	0
26	EEG: A valuable tool to screen for neurodegeneration in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e039696.	0.8	1
27	Phenotypes associated with MAPT duplications. <i>Alzheimer's and Dementia</i> , 2020, 16, e042008.	0.8	0
28	Multimodal screening for neurodegeneration in preclinical Alzheimer's disease using EEG, APOE4 genotype, neuropsychological and MRI data. <i>Alzheimer's and Dementia</i> , 2020, 16, e044027.	0.8	0
29	Accuracy of MRI Classification Algorithms in a Tertiary Memory Center Clinical Routine Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1157-1166.	2.6	19
30	The meta-memory ratio: a new cohort-independent way to measure cognitive awareness in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 57.	6.2	12
31	Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience. <i>Neurobiology of Aging</i> , 2020, 91, 167.e1-167.e9.	3.1	24
32	Amyloid- β^2 in Alzheimer's Disease: A Study of Citation Practices of the Amyloid Cascade Hypothesis Between 1992 and 2019. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1309-1317.	2.6	15
33	A Reliable and Rapid Language Tool for the Diagnosis, Classification, and Follow-Up of Primary Progressive Aphasia Variants. <i>Frontiers in Neurology</i> , 2020, 11, 571657.	2.4	11
34	The ethics of innovation for Alzheimer's disease: the risk of overstating evidence for metabolic enhancement protocols. <i>Theoretical Medicine and Bioethics</i> , 2020, 41, 223-237.	0.8	15
35	Causative Mutations and Genetic Risk Factors in Sporadic Early Onset Alzheimer's Disease Before 51 Years. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 227-243.	2.6	39
36	Which Episodic Memory Performance is Associated with Alzheimer's Disease Biomarkers in Elderly Cognitive Complainers? Evidence from a Longitudinal Observational Study with Four Episodic Memory Tests (Insight-PreAD). <i>Journal of Alzheimer's Disease</i> , 2019, 70, 811-824.	2.6	16

#	ARTICLE	IF	CITATIONS
37	How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years. <i>BMJ Open</i> , 2019, 9, e029663.	1.9	16
38	Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 553-562.	3.7	8
39	Multi-omics signature of brain amyloid deposition in asymptomatic individuals at-risk for Alzheimer's disease: The INSIGHT-preAD study. <i>EBioMedicine</i> , 2019, 47, 518-528.	6.1	36
40	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019, 83, 42-53.	3.1	48
41	Tribute to Anne Bertrand (1978-2018): Neuroradiologist, scientist, teacher and friend. <i>Journal of Neuroradiology</i> , 2019, 46, 155-159.	1.1	0
42	EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. <i>Brain</i> , 2019, 142, 2096-2112.	7.6	131
43	Activity-induced MEMRI cannot detect functional brain anomalies in the APPxPS1-Ki mouse model of Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 1140.	3.3	5
44	Simultaneous quantification of tau and α -synuclein in cerebrospinal fluid by high-resolution mass spectrometry for differentiation of Lewy Body Dementia from Alzheimer's Disease and controls. <i>Analyst</i> , 2019, 144, 6342-6351.	3.5	13
45	First European case of Creutzfeldt-Jakob disease with a PRNP G114V mutation. <i>Cortex</i> , 2019, 117, 407-413.	2.4	3
46	Reproducible evaluation of methods for predicting progression to Alzheimer's disease from clinical and neuroimaging data. , 2019, , .		7
47	Cognitive and neuroimaging features and brain β -amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. <i>Lancet Neurology</i> , 2018, 17, 335-346.	10.2	161
48	Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasia. <i>Neurology</i> , 2018, 90, e1057-e1065.	1.1	13
49	Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: $A\beta_{42}$, total τ , phosphorylated τ , NFL, neurogranin, and YKL40. <i>Alzheimer's and Dementia</i> , 2018, 14, 492-501.	0.8	91
50	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	2.6	215
51	Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. <i>Annals of Nuclear Medicine</i> , 2018, 32, 75-86.	2.2	45
52	P3-279: COGNITION AND LOW VISION: COGEVIS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1185.	0.8	0
53	P4-088: EVOLUTION OF THE AWARENESS OF COGNITIVE DECLINE INDEX OVER 24 MONTHS IN PRECLINICAL ALZHEIMER'S DISEASE IS ASSOCIATED TO BASELINE BRAIN AMYLOID LOAD. <i>Alzheimer's and Dementia</i> , 2018, 14, P1469.	0.8	0
54	O3-12-04: THE NEURONAL COMPENSATION MODEL OF THE PRECLINICAL STAGE OF ALZHEIMER'S DISEASE: RESULTS FROM THE INSIGHT-PRE AD STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1051.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Atrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer's disease cerebrospinal fluid biomarkers. <i>NeuroImage: Clinical</i> , 2018, 20, 1018-1025.	2.7	21
56	Neural correlates of episodic memory in the Memento cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 224-233.	3.7	23
57	Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHT-AD study. <i>Alzheimer's and Dementia</i> , 2018, 14, 1126-1136.	0.8	20
58	Multimorbidity Is Associated with Preclinical Alzheimer's Disease Neuroimaging Biomarkers. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 45, 272-281.	1.5	18
59	COGEVIS: A New Scale to Evaluate Cognition in Patients with Visual Deficiency. <i>Behavioural Neurology</i> , 2018, 2018, 1-7.	2.1	2
60	Miming neurological syndromes improves medical student's long-term retention and delayed recall of neurology. <i>Journal of the Neurological Sciences</i> , 2018, 391, 143-148.	0.6	14
61	Que penser de l'approche mÃ©dicamenteuse prÃ©ventive de la maladie d'Alzheimer ?. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 679-690.	0.0	0
62	Cognitive dissonance resolution depends on episodic memory. <i>Scientific Reports</i> , 2017, 7, 41320.	3.3	20
63	Free and Cued Selective Reminding Test " accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: A large-scale biomarker-characterized monocenter cohort study (ClinAD). <i>Alzheimer's and Dementia</i> , 2017, 13, 913-923.	0.8	75
64	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017, 13, 454-467.	0.8	58
65	Two-level diagnostic classification using cerebrospinal fluid YKL40 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 993-1003.	0.8	39
66	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. <i>Neurochemistry International</i> , 2017, 108, 355-360.	3.8	46
67	Amyloidosis and neurodegeneration result in distinct structural connectivity patterns in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2017, 55, 177-189.	3.1	20
68	17q21.31 duplication causes prominent tau-related dementia with increased MAPT expression. <i>Molecular Psychiatry</i> , 2017, 22, 1119-1125.	7.9	57
69	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1327-1334.	2.6	35
70	[P4-184]: LOW COGNITIVE AWARENESS, BUT NOT COMPLAINT, IS A GOOD MARKER OF PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1333.	0.8	3
71	[P2-379]: ACCURACY OF MRI CLASSIFICATION ALGORITHMS IN A TERTIARY MEMORY CENTER CLINICAL ROUTINE COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P772.	0.8	1
72	[P4-302]: DOES BRAIN AMYLOID DEPOSITION IMPACT EVERYDAY FUNCTIONING IN SUBJECTS WITH COGNITIVE COMPLAINTS? RESULTS FROM THE INSIGHT COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1406.	0.8	0

#	ARTICLE	IF	CITATIONS
73	[P1â€™388]: DIFFERENT STRUCTURAL CONNECTIVITY PATTERNS IN MILD COGNITIVE IMPAIRMENT STRATIFIED BY AMYLOID AND NEURODEGENERATION BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2017, 13, P414.	0.8	0
74	[O2â€™05â€™04]: IN COGNITIVELY NORMAL INDIVIDUALS, THE BEST CONCORDANCE BETWEEN CSF BIOMARKERS AND PET AMYLOID IS OBSERVED WITH THE COMBINATION OF Bâ€™AMYLOID1â€™42 AND PHOSPHORYLATED TAU. <i>Alzheimer's and Dementia</i> , 2017, 13, P562.	0.8	0
75	Alzheimerâ€™s Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 577-583.	2.6	2
76	Cognitive impairment profile in adult patients with Niemann pick type C disease. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 166.	2.7	24
77	Prediction of Amyloidosis from Neuropsychological and MRI Data for Cost Effective Inclusion of Pre-symptomatic Subjects in Clinical Trials. <i>Lecture Notes in Computer Science</i> , 2017, , 357-364.	1.3	1
78	APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. <i>PLoS Medicine</i> , 2017, 14, e1002270.	8.4	358
79	Low Cognitive Awareness, but Not Complaint, is a Good Marker of Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 753-762.	2.6	36
80	P1-394: Prevalence and Characteristics of Patients with Alzheimerâ€™s Disease Eligible for a Disease Modifying Drug (Panacea). , 2016, 12, P584-P584.		0
81	P4-154: SUSPECTED NON-ALZHEIMER DISEASE PATHOPHYSIOLOGY (SNAP) CATEGORIZATION IN THE INSIGHT COHORT. , 2016, 12, P1073-P1074.		0
82	O4-02-01: The Insight Cohort: Baseline Analysis of Structural Mr Imaging in Asymptomatic Subjects at Risk for Alzheimer's Disease. , 2016, 12, P334-P334.		1
83	P3â€™05: Exploring the Anatomical Substrate of Episodic Memory: the Structural Mri Correlates of the Free and Cued Selective Reminding Test in the Memento Cohort. <i>Alzheimer's and Dementia</i> , 2016, 12, P958.	0.8	0
84	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.8	1,318
85	Mechanical stress models of Alzheimer's disease pathology. <i>Alzheimer's and Dementia</i> , 2016, 12, 324-333.	0.8	25
86	Prediction of Alzheimerâ€™s Disease Dementia: Data from the GuidAge Prevention Trial. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 793-804.	2.6	28
87	Acute amnesic encephalopathy in amyloid-Î² oligomerâ€™injected mice is due to their widespread diffusion in vivo. <i>Neurobiology of Aging</i> , 2015, 36, 2043-2052.	3.1	23
88	Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition. <i>Neurobiology of Aging</i> , 2015, 36, 149-156.	3.1	15
89	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , The, 2014, 13, 614-629.	10.2	2,657
90	Detection of volume loss in hippocampal layers in Alzheimer's disease using 7ÂˆT MRI: A feasibility study. <i>NeuroImage: Clinical</i> , 2014, 5, 341-348.	2.7	74

#	ARTICLE	IF	CITATIONS
91	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. <i>Biochemical Pharmacology</i> , 2014, 88, 426-449.	4.4	105
92	Alzheimer disease: From biomarkers to diagnosis. <i>Revue Neurologique</i> , 2013, 169, 744-751.	1.5	22
93	Verbal memory impairment in subcortical ischemic vascular disease. <i>Neurobiology of Aging</i> , 2011, 32, 2172-2182.	3.1	34
94	Pure alexia as a disconnection syndrome: New diffusion imaging evidence for an old concept. <i>Cortex</i> , 2008, 44, 962-974.	2.4	271
95	Differential Patterns of Domain-Specific Cognitive Complaints and Awareness Across the Alzheimer's Disease Spectrum. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	4